CARE

Carter Bankshares is a $4.85B-asset community bank concentrated in NC/VA/SC whose 2025 results (EPS $1.38, +30%; net income $31.4M, +28%) reflect a real recovery — but the stock has gotten ahead of the franchise. Return on equity is only 7.5%, well below a typical bank cost of equity, yet the shares trade at ~1.73x book ($726M cap on $420M equity) and 23.7x earnings — multiples normally reserved for high-ROE specialty banks, not a 7.5%-ROE regional. The most telling tell: the company's own $20M buyback was executed at a $17.78 weighted-average price, and the newly authorized program (Feb 2026, $10M) is now sized small, suggesting management sees less value at $32.74.

The filing language exposes real concentration risk. CRE is 54.5% of total portfolio loans (up from 51.6%), and the MD&A's own segment table flags $187.3M of CRE as special mention/substandard. The hospitality book ($373.5M) carries $51.6M of criticized loans (13.8% of the segment), land ($138.5M) has $36.7M criticized (26.5%), and office holds $25.7M of weakness. Top-10 relationships are 17% of gross loans, and 32.4% of that concentration sits in the 'Other' segment — the same bucket housing the legacy nonaccrual placed on watch in Q2 2023 that the filing references. That single relationship has been the overhang on this name for three years.